These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38143011)
21. The DHX33 RNA Helicase Promotes mRNA Translation Initiation. Zhang Y; You J; Wang X; Weber J Mol Cell Biol; 2015 Sep; 35(17):2918-31. PubMed ID: 26100019 [TBL] [Abstract][Full Text] [Related]
22. The interaction between the helicase DHX33 and IPS-1 as a novel pathway to sense double-stranded RNA and RNA viruses in myeloid dendritic cells. Liu Y; Lu N; Yuan B; Weng L; Wang F; Liu YJ; Zhang Z Cell Mol Immunol; 2014 Jan; 11(1):49-57. PubMed ID: 24037184 [TBL] [Abstract][Full Text] [Related]
23. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500 [TBL] [Abstract][Full Text] [Related]
24. Alternative translation initiation from two in-frame start codons in DHX33 gene. Wang J; Yuan Z; Zhang Y Biochem Biophys Res Commun; 2018 Aug; 502(4):501-507. PubMed ID: 29864424 [TBL] [Abstract][Full Text] [Related]
25. Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents. Wang Y; Nie G; Wang X; Ge W; Zhang Y Bioorg Med Chem Lett; 2023 Nov; 96():129505. PubMed ID: 37838340 [TBL] [Abstract][Full Text] [Related]
26. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477 [TBL] [Abstract][Full Text] [Related]
27. DHX33 Recruits Gadd45a To Cause DNA Demethylation and Regulates a Subset of Gene Transcription. Feng W; Chen S; Wang J; Wang X; Chen H; Ning W; Zhang Y Mol Cell Biol; 2020 Jun; 40(13):. PubMed ID: 32312884 [TBL] [Abstract][Full Text] [Related]
29. Circular RNA ACACA negatively regulated p53-modulated mevalonate pathway to promote colorectal tumorigenesis via regulating miR-193a/b-3p/HDAC3 axis. He F; Liu Q; Liu H; Pei Q; Zhu H Mol Carcinog; 2023 Jun; 62(6):754-770. PubMed ID: 36920044 [TBL] [Abstract][Full Text] [Related]
30. p53 regulates the mevalonate pathway in human glioblastoma multiforme. Laezza C; D'Alessandro A; Di Croce L; Picardi P; Ciaglia E; Pisanti S; Malfitano AM; Comegna M; Faraonio R; Gazzerro P; Bifulco M Cell Death Dis; 2015 Oct; 6(10):e1909. PubMed ID: 26469958 [TBL] [Abstract][Full Text] [Related]
31. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288 [TBL] [Abstract][Full Text] [Related]
33. Dhx33 promotes B-cell growth and proliferation by controlling activation-induced rRNA upregulation. He X; Zhao J; Adilijiang A; Hong P; Chen P; Lin X; Xie J; Du Y; Liu Y; Lin L; Jin HY; Hong Y; Liu WH; Xiao C Cell Mol Immunol; 2023 Mar; 20(3):277-291. PubMed ID: 36631557 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway. Aersilan A; Hashimoto N; Yamagata K; Yokoyama M; Nakayama A; Shi X; Nagano H; Sakuma I; Nohata N; Kinoshita T; Seki N; Rahmutulla B; Kaneda A; Zhahara SN; Gong Y; Nishimura M; Kawauchi S; Kawakami E; Tanaka T Sci Rep; 2022 Nov; 12(1):18443. PubMed ID: 36323841 [TBL] [Abstract][Full Text] [Related]
35. miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33. Zhang CZ; Cao Y; Fu J; Yun JP; Zhang MF Mol Oncol; 2016 Dec; 10(10):1532-1541. PubMed ID: 27693040 [TBL] [Abstract][Full Text] [Related]
36. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer. Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580 [TBL] [Abstract][Full Text] [Related]
37. GSK-3β phosphorylation of DHX33 leads to its ubiquitination mediated protein degradation. Zhang Y; Chen S; Peng C Cell Signal; 2023 Jan; 101():110526. PubMed ID: 36403931 [TBL] [Abstract][Full Text] [Related]
38. An RNA Helicase DHX33 Inhibitor Shows Broad Anticancer Activity via Inducing Ferroptosis in Cancer Cells. Tang X; Deng Y; Liang Y; Liao D; Wen F; Zhang Y ACS Omega; 2024 Jul; 9(26):28372-28384. PubMed ID: 38973855 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53. Xu D; Tong X; Sun L; Li H; Jones RD; Liao J; Yang GY Mol Carcinog; 2019 Nov; 58(11):2052-2064. PubMed ID: 31397499 [TBL] [Abstract][Full Text] [Related]
40. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Lee T; Pelletier J Oncotarget; 2017 May; 8(19):30908-30921. PubMed ID: 28427210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]